CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITOR AND METHODS FOR ITS PREPARATION

The present application relates to a novel crystalline form of ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (Compound 1). The present application also relates to a method of preparing Compound 1 and a method of preparing crystalline polymorph Form A of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LAWSON, Jon P, SPRINGER, John, DECRESCENZO, Gary
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present application relates to a novel crystalline form of ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (Compound 1). The present application also relates to a method of preparing Compound 1 and a method of preparing crystalline polymorph Form A of Compound 1. Additional aspects of the present application relate to pharmaceutical compositions comprising Compound 1 formed from the crystalline form or the crystalline form of Compound 1. La présente invention concerne une nouvelle forme cristalline d'éthyle (R )-4-((1-(2-cyanoacétyl)pipéridin-3-yl) amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (composé 1). La présente invention concerne également un procédé de préparation du composé 1 et un procédé de préparation de la forme polymorphe cristalline A du composé 1. D'autres aspects de la présente invention concernent des compositions Pharmaceutiques comprenant le composé 1 formé à partir de La forme cristalline ou de la forme cristalline du composé 1.